Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma

NCT01238861 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT01238861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01238861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma
Lead sponsor
MedImmune LLC
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2010
Completion date
August 31, 2013
Enrollment
964 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

asthma